A Parkinson's Pill That Skips Dopamine Just Won Its Phase 3 Trial
On Oct. 7 Cerevance said once-daily solengepras cut daily OFF time by 0.61 hours versus placebo in its 341-person ARISE trial, working through a new brain target called GPR6. Next stop is the FDA.
So basically: A Boston biotech called Cerevance said Wednesday, Oct. 7, that its once-a-day Parkinson’s pill, solengepras, hit its main goal in a Phase 3 trial. It cut the time patients spend in bad “OFF” stretches. What makes it different is how it works. It does not touch dopamine, which almost every Parkinson’s drug does.
First, what OFF time means
Parkinson’s kills the brain cells that make dopamine, which helps your body move smoothly. Lose it, and you get tremors, stiffness, and slow movement.
The standard treatment is levodopa, a drug the brain turns into dopamine. It works, but over the years it starts wearing off between doses.
When it wears off, symptoms come back. Doctors call that OFF time. When the drug is working, that is ON time.
People in this trial were already on levodopa and other Parkinson’s meds. They still averaged 5.65 hours of OFF time every day.
What the trial found
The trial, called ARISE, enrolled 341 people in the U.S., Europe, the U.K., and Australia.
Everyone kept taking their usual meds. On top of that, they got one of three things once a day for 12 weeks:
- Solengepras 75 mg (114 people)
- Solengepras 150 mg (113 people)
- A placebo (114 people)
91% of participants finished the trial.
The main result was for the 150 mg dose. It cut daily OFF time by 0.61 hours more than placebo at week 12. Patients on the drug dropped 1.56 hours from where they started. Placebo patients dropped 0.95 hours.
The gap showed up fast. At week 2, the first check-in, the drug was already 0.75 hours ahead.
Other results at 150 mg, compared with placebo:
- ON time without troublesome involuntary movements went up 0.60 hours
- A daily-living movement score improved by 1.91 points
- Daytime sleepiness improved by 0.98 points
- A quality-of-life score improved by 2.87 points, though that one was exploratory
Side effects
3.5% of people quit because of side effects in all three groups, including placebo. There were no serious side effects in the 150 mg group.
The most common ones at 150 mg were headache (8.0% vs 3.5% on placebo), urinary tract infections (8.0% vs 6.1%), insomnia (6.2% vs 0.9%), and nausea (6.2% vs 1.8%). Involuntary movements showed up in 4.4% of people versus 1.8% on placebo.
Why skipping dopamine matters
Most add-on Parkinson’s drugs either boost dopamine or copy it. Those can cause their own problems, like extra involuntary movements and sleepiness.
Solengepras goes after a receptor called GPR6. It sits on brain cells in a movement circuit that acts like a brake. When dopamine is lost, that brake gets stuck on. Blocking GPR6 is meant to ease off the brake without messing with dopamine at all.
If it gets approved, Cerevance says it would be the first GPR6 drug for Parkinson’s.
The comeback angle
This drug almost didn’t make it here. Fierce Biotech notes it missed its main goal in an April 2025 Phase 2 trial, when it was tested alone in people who were not yet on other meds.
This time it was an add-on to levodopa, and it worked.
It is a busy moment for Parkinson’s. Fierce says AbbVie won FDA approval last month for tavapadon, from its $8.7 billion Cerevel deal. On Monday, Genentech paid Alector $100 million for a Parkinson’s enzyme therapy.
What happens next
Cerevance plans to meet with the FDA about filing for approval. There is no filing date yet. The data were presented at the MDS Congress in Seoul.
Parkinson’s affects more than 10 million people worldwide and about 1 million in the U.S., according to the company.
My take
0.61 hours sounds small. It is about 37 minutes a day.
But it comes on top of drugs people already take. For someone who can barely move during an OFF stretch, 37 minutes back every day is real.
The more interesting part is the new mechanism. A pill that helps without hitting dopamine could mean fewer of the side effects that pile up over years of treatment. The sleepiness result points that way.
Still, this is one trial and the company’s own release. I want to see the full data published, the 75 mg results, and what the FDA says. A Phase 2 miss followed by a Phase 3 win is a good story. An approval is a better one.
So basically — pass it on.